Technology

AddToAny

Google+ Facebook Twitter Twitter

UK biomedical catalyst award

Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst programme.

Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias.

centauritherapeutics.com

Related Articles

Cila Vircell

New serology assays

Vircell has added a number of new assays to its VirClia range, enhancing the extensive portfolio of chemiluminescent monotests for infectious disease serology.

Beta cells strand

Blood glucose and type 1 diabetes

A study shows that a gene therapy approach can lead to long-term survival for functional beta cells, as well as normal blood glucose levels for an extended period of time in mice with type 1 diabetes. 

Triple negative breast cancer cell

Fighting breast cancer

A combination of oncolytic viruses and checkpoint inhibitors could be more successful than traditional treatments in fighting breast cancer, and possibly other cancers too.

Science news in numbers

Science news in numbers: February

A breakdown of science news this month.

Top